Welcome to our dedicated page for Respirerx Pharma news (Ticker: RSPI), a resource for investors and traders seeking the latest updates and insights on Respirerx Pharma stock.
Respirex Pharma (RSPI) delivers innovative therapeutic solutions through cutting-edge biopharmaceutical research. This news hub provides investors and industry professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company’s trajectory.
Access a centralized repository of press releases and verified news covering RSPI’s advancements in neurology, respiratory therapies, and translational medicine. Track critical updates including clinical trial progress, research partnerships, and peer-reviewed publication highlights that underscore the company’s scientific rigor.
Our curated collection ensures you stay informed about RSPI’s operational achievements without speculative commentary. Bookmark this page for efficient monitoring of earnings announcements, intellectual property developments, and collaborative ventures driving therapeutic innovation.
RespireRx Pharmaceuticals (Ticker: RSPI) issued a year-end letter summarizing 2025 restructuring, financings, grants, and clinical progress. The company formed EndeavourRx (Jan 27, 2025) to develop AMPAkines and GABAkines and created ResolutionRx (Australia) to advance a dronabinol program for obstructive sleep apnea and access Australian R&D tax incentives.
Key funding and programs: a $1,793,411 DoD award for Phase 2A/2B CX1739 spinal cord injury trials; an NIH/NINDS $1,499,869 SBIR award$45 million allocated $15M to ResolutionRx, $25M to EndeavourRx, $5M to RespireRx. The company amended a patent license with UWM and plans ASX listing for ResolutionRx.
Regulatory note: the SEC issued a final Order revoking RSPI registration (effective Nov 14, 2025) under Section 12(j) for failure to file periodic reports since the Form 10-Q for period ended Sept 30, 2023.
RespireRx (OTC:RSPI) received an NIH/NINDS SBIR Notice of Award and amended its patent license with the University of Wisconsin Research Foundation.
The NIH award is $1,499,869 for the budget period Sep 23, 2025–Aug 31, 2026; the project spans Sep 23, 2025–Aug 31, 2027 and the two‑year application requested $2,999,738. The grant supports preclinical toxicology and IND‑enabling work for lead GABAkine KRM‑II‑81 to treat epilepsy. The amended license updates milestone payments, royalties, patent cost timing, and replaces prior equity with a fixed exit fee.
RespireRx Pharmaceuticals (OTC: RSPI) announced receipt of a Securities and Exchange Commission order that revoked registration of its securities pursuant to Section 12(j) of the Securities Exchange Act, effective November 14, 2025. The SEC found RSPI failed to file periodic reports after its Form 10-Q for the period ended September 30, 2023, and noted unsolicited quotations on the OTC Link Expert Market.
RSPI submitted an Offer of Settlement on September 30, 2025; there is no monetary fine. The company plans to re-register common stock by filing a Form 10 after December 31, 2025 with audited financials for Dec 31, 2024 and Dec 31, 2025; a Form 10 filed under Section 12(g) is understood to become effective 60 days after filing.
RespireRx Pharmaceuticals (NASDAQ:RSPI) has commenced a Regulation D, Rule 506(c) private placement targeting up to $45 million across three affiliated entities to fund R&D, clinical programs, and corporate needs.
Planned capital allocation: $15 million to ResolutionRx for a proprietary dronabinol formulation for obstructive sleep apnea including PK/PD studies and a Phase 3 trial; $25 million to EndeavourRx for AMPAkines (CX1739, CX717) and GABAkines (KRM-II-81) development, supported by a U.S. Department of Defense grant and a pending NIH/NINDS SBIR award; and $5 million to RespireRx parent for corporate operations, governance, and IP. Castle Placement is the exclusive placement agent.
RespireRx Pharmaceuticals has issued a stockholder letter highlighting its 2024 progress and 2025 outlook. The company reported fourteen peer-reviewed publications in 2024, with two additional papers published in 2025. Their collaborator, Shirley Ryan AbilityLab, received a $1.8 million DoD grant for Phase 2A and 2B clinical trials testing CX1739 in spinal cord injured patients.
The company faces several challenges, including non-compliance with SEC reporting requirements, insufficient available common stock shares, and difficulties implementing the DoD grant. To address these issues, RespireRx has established two subsidiaries: ResolutionRx in Australia for cannabinoid program development, and EndeavourRx for neuromodulator programs.
The company has amended its preferred stock certificates to enable capital raising and is pursuing strategic collaborations, research partnerships, and grant opportunities. A high-scoring SBIR grant application for their GABAkines program is under review.
RespireRx Pharmaceuticals announced a $1.8 million award from the Department of Defense (DOD) to fund Phase 2 clinical trials for CX1739, their lead AMPAkine, aimed at improving bladder function in patients with spinal cord injury (SCI). Conducted by Shirley Ryan AbilityLab and led by Dr. Milap Sandhu, the study will have two stages: Phase 2A for single dose safety and efficacy, and Phase 2B for placebo-controlled trials. RespireRx has been allocated $252,200 for manufacturing and regulatory submissions. Clinical trials are projected to begin by Q4 2024. CX1739 has previously shown promising results in preclinical animal studies and early human trials.
FAQ
What is the current stock price of Respirerx Pharma (RSPI)?
What is the market cap of Respirerx Pharma (RSPI)?
